Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GEN1056 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| GEN1056 | BIOLOGICAL | GEN1056 will be administered as an intravenous (IV) infusion. The dose levels will be determined by the starting dose and the escalation steps taken in the trial in Part 1. In Part 2, the dose and schedule will be decided based on data outcome from Part 1. |
GEN1056 is an investigational monoclonal antibody being studied for the treatment of solid tumors in adults. It is currently in Phase 1 clinical development, with a completed trial evaluating its safety and antitumor activity in participants with advanced solid tumors.
GEN1056 is a monoclonal antibody, but its specific molecular target has not been disclosed. The drug is being investigated for its antitumor activity in advanced solid tumors, though the exact mechanism of action is not publicly detailed.
GEN1056 is being developed by Genmab A/S, a biotechnology company listed on the Nasdaq under the ticker GMAB. The company is conducting clinical research on this investigational antibody for oncology indications.
GEN1056 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational, meaning it has not yet been approved by regulatory authorities and is still undergoing clinical evaluation.
GEN1056 has one completed clinical trial, NCT05586321, which was a Phase 1 study titled "Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors." The trial enrolled 26 participants and was not randomized or blinded.
GEN1056 is the investigational name used by Genmab for this monoclonal antibody. No alternative names have been publicly associated with this drug in the available clinical trial information.